Rituximab versus leflunomide in methotrexate non responders rheumatoid arthritis patients
Phase 3
- Conditions
- Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified
- Registration Number
- CTRI/2021/07/035221
- Lead Sponsor
- Institute of Postgraduate Medical Education and Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with active rheumatoid arthritis despite treatment with 10-25 mg/week of Methotrexate for at least 3 months
Exclusion Criteria
a. Patients who have been treated with Leflunomide or Rituximab previously
b. ACR functional class IV
c. Presence of an overlapping disease
d. History of recurrent infections in the past
e. Pregnant or lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method